<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03087851</url>
  </required_header>
  <id_info>
    <org_study_id>2015-005529-37</org_study_id>
    <nct_id>NCT03087851</nct_id>
  </id_info>
  <brief_title>Treatment With Zoledronic Acid Subsequent to Denosumab in Osteoporosis</brief_title>
  <acronym>ZOLARMAB</acronym>
  <official_title>Treatment With Zoledronic Acid Subsequent to Denosumab in Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aarhus University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Denosumab is an antibody against receptor-activator of nuclear factor kappa-B ligand that&#xD;
      prevents recruitment and differentiation of mature osteoclasts. Treatment markedly decrease&#xD;
      bone resorption and fracture risk, and many patients will reach osteopenic bone mineral&#xD;
      density (BMD) levels on treatment with denosumab. The treatment effect on bone turnover and&#xD;
      BMD has, however, been demonstrated to be reversible. This study will show if the bone mass&#xD;
      can be maintained by administrating zoledronic acid and if timing of the first dose of&#xD;
      zoledronic acid after last dose of denosumab matters.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Denosumab is an antibody against receptor-activator of nuclear factor kappa-B&#xD;
      ligand that prevents recruitment and differentiation of osteoclasts. Treatment decreases bone&#xD;
      resorption and fracture risk. After discontinuation, however, bone resorption increases and&#xD;
      the bone mass gained during 2 years of therapy is lost within 1 year. At present denosumab&#xD;
      treatment is considered to be life-long.&#xD;
&#xD;
      Aim: To investigate if infusion of zoledronic acid can prevent increases in bone turnover and&#xD;
      bone loss in patients previously treated with denosumab and if there is difference between&#xD;
      infusing zoledronic acid at six or nine months after the last injection of denosumab or when&#xD;
      bone turnover is increased.&#xD;
&#xD;
      Methods: A randomized open label, interventional study in 60 patients investigating if&#xD;
      treatment with zoledronic acid prevents bone loss after denosumab treatment when&#xD;
      administrated six or nine months after last injection of deno-sumab or when bone turnover is&#xD;
      increased. Forty patients will be allocated to the two intervention groups and 20 patients&#xD;
      will be followed without treatment for up to 12 months after the last denosumab treatment.&#xD;
      The patients in the observation group and the nine months group will be monitored monthly and&#xD;
      if s-carboxy-terminal collagen cross-links (s-CTX) increases above 1.26ug/l (50% above the&#xD;
      normal range for postmenopausal women and elderly men) infusion of zoledronic acid will be&#xD;
      administered. Furthermore, a DXA scan (lumbar spine and hip sites) will be performed after&#xD;
      three months in the observation group. If BMD has decreased more than 5% at any site,&#xD;
      infusion of zoledronic acid will be administered. Finally, if a patient in the 9 months group&#xD;
      or the in the observation group suffers an osteoporotic clinical vertebral or hip fracture,&#xD;
      infusion of zoledronic acid will be administered.&#xD;
&#xD;
      The patients will be monitored with DXA 6, 12 and 24 months after the infusion of zoledronic&#xD;
      acid. Zoledronic acid will be re-administered if BMD has decreased more than 5% at the lumbar&#xD;
      spine, total hip or femoral neck. If s-CTX in-creases above 1.26 ug/l during the 2nd year a&#xD;
      second infusion of zoledronic acid will be administered.&#xD;
&#xD;
      Perspectives: Many patients will reach osteopenic BMD levels on treatment with denosumab,&#xD;
      however the treatment effect on bone turnover and BMD has been demonstrated to be reversible&#xD;
      and it is therefore important to find out if denosumab treatment can be discontinued and bone&#xD;
      mass maintained by other measures. This study will show if the bone mass can be maintained by&#xD;
      administrating zoledronic acid and if timing of the first dose of zoledronic acid after last&#xD;
      dose of denosumab matters. If bone loss can be prevented by zoledronic acid expenses on&#xD;
      otherwise life-long denosumab treatment can be saved and long-term side effects of denosumab&#xD;
      (atypical femur fractures and osteone-crosis of the jaw) can be prevented.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 13, 2017</start_date>
  <completion_date type="Actual">August 1, 2020</completion_date>
  <primary_completion_date type="Actual">August 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Lumbar Spine BMD From Baseline to 6 Months After the Zoledronic Acid Infusion.</measure>
    <time_frame>baseline to 6 months after the zoledronic acid infusion</time_frame>
    <description>Change in lumbar spine BMD from baseline to 6 months after the zoledronic acid infusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Fail to Maintain BMD</measure>
    <time_frame>2 years after the first ZOL treatment</time_frame>
    <description>Failure is defined as â‰¥ 3 % BMD loss at the lumbar spine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in BMD From Baseline to One Year After the Zoledronic Acid Infusion.</measure>
    <time_frame>from baseline to one year after the zoledronic acid infusion</time_frame>
    <description>Changes in lumbar spine BMD from baseline to one year after the zoledronic acid infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in BMD From Baseline to Two Years After the Zoledronic Acid Infusion.</measure>
    <time_frame>from baseline to two years after the zoledronic acid infusion.</time_frame>
    <description>Changes in lumbar spine BMD from baseline to two years after the zoledronic acid infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Cortical Porosity Measured by High-resolution Peripheral Quantitative Computed Tomography (HR-pQCT) Scan at the Radius and Tibia From Baseline to One Year After the Zoledronic Acid Infusion.</measure>
    <time_frame>from baseline to one year after the zoledronic acid infusion.</time_frame>
    <description>Changes in cortical porosity measured by high-resolution peripheral quantitative computed tomography (HR-pQCT) scan at the radius and tibia from baseline to one year after the zoledronic acid infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in p-CTX From Baseline to Six Months After the Zoledronic Acid Infusion.</measure>
    <time_frame>from baseline to six months after the zoledronic acid infusion.</time_frame>
    <description>Changes in p-CTX from baseline to six months after the zoledronic acid infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in p-CTX From Baseline to 12 Months After the Zoledronic Acid Infusion.</measure>
    <time_frame>from baseline to 12 months after the zoledronic acid infusion.</time_frame>
    <description>Changes in p-CTX from baseline to 12 months after the zoledronic acid infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morphometric Vertebral Fractures Assessed by Vertebral Fracture Assessment (VFA) One and Two Years After the Zoledronic Acid Infusion.</measure>
    <time_frame>one and two years after the zoledronic acid infusion.</time_frame>
    <description>Morphometric vertebral fractures assessed by vertebral fracture assessment (VFA) one and two years after the zoledronic acid infusion.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>6-month group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zoledronic acid will be administered at study day 0. If s-CTX increases above 1.26 ug/l or BMD decreases more than 5% at any site a second infusion of zoledronic acid will be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9-months group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zoledronic acid will be administered depending on increase in s-CTX (above 1.26 ug/l) or the occurrence of an osteoporotic clinical vertebral or hip fracture, but no later than at month 3.&#xD;
If s-CTX increases above 1.26 ug/l or BMD decreases more than 5% at any site a second infusion of zoledronic acid will be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zoledronic acid will be administered depending on increase in s-CTX (above 1.26 ug/l), decrease in BMD (more than 5% at any site), or the occurrence of an osteoporotic clinical vertebral or hip fracture, but no later than at month 6.&#xD;
If s-CTX increases above 1.26 ug/l or BMD decreases more than 5% at any site a second infusion of zoledronic acid will be administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic Acid</intervention_name>
    <description>Intravenous infusion of 5 mg zoledronic acid</description>
    <arm_group_label>6-month group</arm_group_label>
    <arm_group_label>9-months group</arm_group_label>
    <arm_group_label>Observation group</arm_group_label>
    <other_name>Zoledronate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Postmenopausal women (postmenopausal for at least two years)&#xD;
&#xD;
          -  Men above 50 years&#xD;
&#xD;
          -  Treatment for at least two years with denosumab&#xD;
&#xD;
          -  Last denosumab injection less than five months ago&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Low-energy vertebral fracture at any time&#xD;
&#xD;
          -  Low-energy hip fracture within the last 12 months&#xD;
&#xD;
          -  BMD T-score &lt; -2,5 (lumbar spine, total hip or femoral neck)&#xD;
&#xD;
          -  Alendronate treatment for more than three years prior to denosumab treatment&#xD;
&#xD;
          -  Ongoing treatment with glucocorticoids&#xD;
&#xD;
          -  Metabolic bone disease&#xD;
&#xD;
          -  Hormone replacement therapy&#xD;
&#xD;
          -  Cancer&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) &lt; 35 mL/min&#xD;
&#xD;
          -  Allergy to zoledronic acid&#xD;
&#xD;
          -  Hypocalcaemia&#xD;
&#xD;
          -  Contraindications for zoledronic acid according to the SPC&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bente L Langdahl, MD PhD DMSc</last_name>
    <role>Study Director</role>
    <affiliation>Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Denmark</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK, San Martin J, Dansey R. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov. 2012 May;11(5):401-19. doi: 10.1038/nrd3705. Review.</citation>
    <PMID>22543469</PMID>
  </reference>
  <reference>
    <citation>Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C; FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009 Aug 20;361(8):756-65. doi: 10.1056/NEJMoa0809493. Epub 2009 Aug 11. Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914.</citation>
    <PMID>19671655</PMID>
  </reference>
  <reference>
    <citation>Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J; Amg Bone Loss Study Group. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008 Aug;43(2):222-9. doi: 10.1016/j.bone.2008.04.007. Epub 2008 Apr 26.</citation>
    <PMID>18539106</PMID>
  </reference>
  <reference>
    <citation>KoldkjÃ¦r SÃ¸lling AS, HarslÃ¸f T, Kaal A, Rejnmark L, Langdahl B. Hypercalcemia after discontinuation of long-term denosumab treatment. Osteoporos Int. 2016 Jul;27(7):2383-2386. doi: 10.1007/s00198-016-3535-5. Epub 2016 Apr 20.</citation>
    <PMID>27098536</PMID>
  </reference>
  <reference>
    <citation>Aubry-Rozier B, Gonzalez-Rodriguez E, Stoll D, Lamy O. Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. Osteoporos Int. 2016 May;27(5):1923-5. doi: 10.1007/s00198-015-3380-y. Epub 2015 Oct 28.</citation>
    <PMID>26510845</PMID>
  </reference>
  <reference>
    <citation>Anastasilakis AD, Makras P. Multiple clinical vertebral fractures following denosumab discontinuation. Osteoporos Int. 2016 May;27(5):1929-30. doi: 10.1007/s00198-015-3459-5. Epub 2015 Dec 22.</citation>
    <PMID>26694593</PMID>
  </reference>
  <reference>
    <citation>Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M; American Society for Bone and Mineral Research. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010 Nov;25(11):2267-94. doi: 10.1002/jbmr.253. Erratum in: J Bone Miner Res. 2011 Aug;26(8):1987.</citation>
    <PMID>20842676</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 13, 2017</study_first_submitted>
  <study_first_submitted_qc>March 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2017</study_first_posted>
  <results_first_submitted>November 26, 2020</results_first_submitted>
  <results_first_submitted_qc>December 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 14, 2021</results_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Anne Sophie SÃ¸lling</investigator_full_name>
    <investigator_title>MD, PhD student</investigator_title>
  </responsible_party>
  <keyword>Denosumab</keyword>
  <keyword>Bone turnover markers</keyword>
  <keyword>Bone mineral density</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 29, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/51/NCT03087851/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>We recruited participants from the Department of Endocrinology, Aarhus University Hospital, Denmark and via advertisements in newspapers and online. The Danish Health Data Authority provided two data extractions, with information on patients living in the Central Region of Denmark, who had redeemed a minimum of 5 prescriptions for denosumab (DMAB) within the last 3 years.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>6-month Group</title>
          <description>Zoledronate: administrated at baseline.&#xD;
Zoledronate re-adminisrated:&#xD;
If p-C-terminal telopeptide of type 1 collagen (p-CTX) increases above 1.26 ug/l or bone mineral density (BMD) decreases more than 5% at any site.</description>
        </group>
        <group group_id="P2">
          <title>9-months Group</title>
          <description>Zoledronate: administrated depending on increase in p-CTX (above 1.26 ug/l) or the occurrence of an osteoporotic clinical vertebral or hip fracture, but no later than at month 3.&#xD;
Zoledronate re-administrated:&#xD;
If p-CTX increases above 1.26 ug/l or BMD decreases more than 5% at any site.</description>
        </group>
        <group group_id="P3">
          <title>Observation Group</title>
          <description>Zoledronate: administrated depending on increase in p-CTX (above 1.26 ug/l), decrease in BMD (more than 5%), or the occurrence of an osteoporotic clinical vertebral or hip fracture, but no later than at month 6.&#xD;
Zoledronate re-administrated:&#xD;
If p-CTX increases above 1.26 ug/l or BMD decreases more than 5% at any site.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdraw on medical grounds</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>6-month Group</title>
          <description>Treated with zoledronate 5 mg</description>
        </group>
        <group group_id="B2">
          <title>9-months Group</title>
          <description>Treated with zoledronate 5 mg</description>
        </group>
        <group group_id="B3">
          <title>Observation Group</title>
          <description>Treated with zoledronate 5 mg</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="21"/>
            <count group_id="B4" value="61"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" spread="8"/>
                    <measurement group_id="B2" value="65" spread="7"/>
                    <measurement group_id="B3" value="69" spread="9"/>
                    <measurement group_id="B4" value="68" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lumbar spine BMD</title>
          <units>g/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0,880" spread="0.055"/>
                    <measurement group_id="B2" value="0,878" spread="0,063"/>
                    <measurement group_id="B3" value="0,871" spread="0,089"/>
                    <measurement group_id="B4" value="0,876" spread="0,069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Lumbar Spine BMD From Baseline to 6 Months After the Zoledronic Acid Infusion.</title>
        <description>Change in lumbar spine BMD from baseline to 6 months after the zoledronic acid infusion.</description>
        <time_frame>baseline to 6 months after the zoledronic acid infusion</time_frame>
        <population>Change in lumbar spine BMD from baseline to 6 months after the zoledronic acid infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>6-month Group</title>
            <description>n=20</description>
          </group>
          <group group_id="O2">
            <title>9-months Group</title>
            <description>n=20</description>
          </group>
          <group group_id="O3">
            <title>Observation Group</title>
            <description>n=21</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lumbar Spine BMD From Baseline to 6 Months After the Zoledronic Acid Infusion.</title>
          <description>Change in lumbar spine BMD from baseline to 6 months after the zoledronic acid infusion.</description>
          <population>Change in lumbar spine BMD from baseline to 6 months after the zoledronic acid infusion.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="0.9"/>
                    <measurement group_id="O2" value="-4.3" spread="1.1"/>
                    <measurement group_id="O3" value="-3.0" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Fail to Maintain BMD</title>
        <description>Failure is defined as â‰¥ 3 % BMD loss at the lumbar spine</description>
        <time_frame>2 years after the first ZOL treatment</time_frame>
        <population>Number of Participants Who Fail to Maintain lumbar spine BMD from baseline to 24 months after the first ZOL</population>
        <group_list>
          <group group_id="O1">
            <title>6-month Group</title>
            <description>n=20</description>
          </group>
          <group group_id="O2">
            <title>9-months Group</title>
            <description>n=20</description>
          </group>
          <group group_id="O3">
            <title>Observation Group</title>
            <description>n=21</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Fail to Maintain BMD</title>
          <description>Failure is defined as â‰¥ 3 % BMD loss at the lumbar spine</description>
          <population>Number of Participants Who Fail to Maintain lumbar spine BMD from baseline to 24 months after the first ZOL</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in BMD From Baseline to One Year After the Zoledronic Acid Infusion.</title>
        <description>Changes in lumbar spine BMD from baseline to one year after the zoledronic acid infusion.</description>
        <time_frame>from baseline to one year after the zoledronic acid infusion</time_frame>
        <population>Changes in lumbar spine BMD from baseline to one year after the zoledronic acid infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>6-month Group</title>
            <description>n=20</description>
          </group>
          <group group_id="O2">
            <title>9-months Group</title>
            <description>n=20</description>
          </group>
          <group group_id="O3">
            <title>Observation Group</title>
            <description>n=21</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in BMD From Baseline to One Year After the Zoledronic Acid Infusion.</title>
          <description>Changes in lumbar spine BMD from baseline to one year after the zoledronic acid infusion.</description>
          <population>Changes in lumbar spine BMD from baseline to one year after the zoledronic acid infusion.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.8" spread="0.7"/>
                    <measurement group_id="O2" value="-4.1" spread="1.1"/>
                    <measurement group_id="O3" value="-4.7" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in BMD From Baseline to Two Years After the Zoledronic Acid Infusion.</title>
        <description>Changes in lumbar spine BMD from baseline to two years after the zoledronic acid infusion.</description>
        <time_frame>from baseline to two years after the zoledronic acid infusion.</time_frame>
        <population>Changes in lumbar spine BMD from baseline to two years after the zoledronic acid infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>6-month Group</title>
            <description>n=20</description>
          </group>
          <group group_id="O2">
            <title>9-months Group</title>
            <description>n=20</description>
          </group>
          <group group_id="O3">
            <title>Observation Group</title>
            <description>n=21</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in BMD From Baseline to Two Years After the Zoledronic Acid Infusion.</title>
          <description>Changes in lumbar spine BMD from baseline to two years after the zoledronic acid infusion.</description>
          <population>Changes in lumbar spine BMD from baseline to two years after the zoledronic acid infusion.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="0.8"/>
                    <measurement group_id="O2" value="-4.1" spread="0.8"/>
                    <measurement group_id="O3" value="-4.3" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Cortical Porosity Measured by High-resolution Peripheral Quantitative Computed Tomography (HR-pQCT) Scan at the Radius and Tibia From Baseline to One Year After the Zoledronic Acid Infusion.</title>
        <description>Changes in cortical porosity measured by high-resolution peripheral quantitative computed tomography (HR-pQCT) scan at the radius and tibia from baseline to one year after the zoledronic acid infusion.</description>
        <time_frame>from baseline to one year after the zoledronic acid infusion.</time_frame>
        <population>Changes in cortical porosity at the radius from baseline to one year after the zoledronic acid infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>6-month Group</title>
            <description>n=20</description>
          </group>
          <group group_id="O2">
            <title>9-months Group</title>
            <description>n=20</description>
          </group>
          <group group_id="O3">
            <title>Observation Group</title>
            <description>n=21</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Cortical Porosity Measured by High-resolution Peripheral Quantitative Computed Tomography (HR-pQCT) Scan at the Radius and Tibia From Baseline to One Year After the Zoledronic Acid Infusion.</title>
          <description>Changes in cortical porosity measured by high-resolution peripheral quantitative computed tomography (HR-pQCT) scan at the radius and tibia from baseline to one year after the zoledronic acid infusion.</description>
          <population>Changes in cortical porosity at the radius from baseline to one year after the zoledronic acid infusion.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="7.4"/>
                    <measurement group_id="O2" value="-1.6" spread="6.7"/>
                    <measurement group_id="O3" value="-4.2" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in p-CTX From Baseline to Six Months After the Zoledronic Acid Infusion.</title>
        <description>Changes in p-CTX from baseline to six months after the zoledronic acid infusion.</description>
        <time_frame>from baseline to six months after the zoledronic acid infusion.</time_frame>
        <population>Changes in p-CTX from baseline to six months after the zoledronic acid infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>6-month Group</title>
            <description>n=20</description>
          </group>
          <group group_id="O2">
            <title>9-months Group</title>
            <description>n=20</description>
          </group>
          <group group_id="O3">
            <title>Observation Group</title>
            <description>n=21</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in p-CTX From Baseline to Six Months After the Zoledronic Acid Infusion.</title>
          <description>Changes in p-CTX from baseline to six months after the zoledronic acid infusion.</description>
          <population>Changes in p-CTX from baseline to six months after the zoledronic acid infusion.</population>
          <units>ug/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" spread="0.35"/>
                    <measurement group_id="O2" value="0.47" spread="0.24"/>
                    <measurement group_id="O3" value="0.47" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in p-CTX From Baseline to 12 Months After the Zoledronic Acid Infusion.</title>
        <description>Changes in p-CTX from baseline to 12 months after the zoledronic acid infusion.</description>
        <time_frame>from baseline to 12 months after the zoledronic acid infusion.</time_frame>
        <population>Changes in p-CTX from baseline to 12 months after the zoledronic acid infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>6-month Group</title>
            <description>n=20</description>
          </group>
          <group group_id="O2">
            <title>9-months Group</title>
            <description>n=20</description>
          </group>
          <group group_id="O3">
            <title>Observation Group</title>
            <description>n=21</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in p-CTX From Baseline to 12 Months After the Zoledronic Acid Infusion.</title>
          <description>Changes in p-CTX from baseline to 12 months after the zoledronic acid infusion.</description>
          <population>Changes in p-CTX from baseline to 12 months after the zoledronic acid infusion.</population>
          <units>ug/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread="0.23"/>
                    <measurement group_id="O2" value="0.40" spread="0.20"/>
                    <measurement group_id="O3" value="0.49" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morphometric Vertebral Fractures Assessed by Vertebral Fracture Assessment (VFA) One and Two Years After the Zoledronic Acid Infusion.</title>
        <description>Morphometric vertebral fractures assessed by vertebral fracture assessment (VFA) one and two years after the zoledronic acid infusion.</description>
        <time_frame>one and two years after the zoledronic acid infusion.</time_frame>
        <population>Morphometric vertebral fractures assessed by vertebral fracture assessment (VFA) two years after the zoledronic acid infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>6-month Group</title>
            <description>n=20</description>
          </group>
          <group group_id="O2">
            <title>9-months Group</title>
            <description>n=20</description>
          </group>
          <group group_id="O3">
            <title>Observation Group</title>
            <description>n=21</description>
          </group>
        </group_list>
        <measure>
          <title>Morphometric Vertebral Fractures Assessed by Vertebral Fracture Assessment (VFA) One and Two Years After the Zoledronic Acid Infusion.</title>
          <description>Morphometric vertebral fractures assessed by vertebral fracture assessment (VFA) one and two years after the zoledronic acid infusion.</description>
          <population>Morphometric vertebral fractures assessed by vertebral fracture assessment (VFA) two years after the zoledronic acid infusion.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 - 2.5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>6-month Group</title>
          <description>Zoledronate: administrated at baseline.&#xD;
Zoledronate re-administrated: If s-CTX increases above 1.26 ug/l or BMD decreases more than 5% at any site.</description>
        </group>
        <group group_id="E2">
          <title>9-months Group</title>
          <description>Zoledronate: administrated depending on increase in s-CTX (above 1.26 ug/l) or the occurrence of an osteoporotic clinical vertebral or hip fracture, but no later than at month 3.&#xD;
Zoledronate re-administrated: If s-CTX increases above 1.26 ug/l or BMD decreases more than 5% at any site.</description>
        </group>
        <group group_id="E3">
          <title>Observation Group</title>
          <description>Zoledronate: administrated depending on increase in s-CTX (above 1.26 ug/l), decrease in BMD (more than 5% at any site), or the occurrence of an osteoporotic clinical vertebral or hip fracture, but no later than at month 6.&#xD;
Zoledronate re-administrated: If s-CTX increases above 1.26 ug/l or BMD decreases more than 5% at any site.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection (unspecified) + Musculoskeletal symptoms</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="20"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="20"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Flu-like symptoms after ZOL treatment</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="20"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Open-label design, no assessment by VFA or X-ray of VFx at baseline, changes in treatment not in accordance with the protocol. Information about BMD before initiation of DMAB is not available and the BMD loss can therefore not be evaluated in the context of the BMD gain during DMAB. Our p-CTX cutoff was 50% above the normal range for postmenopausal women and elderly men and it cannot be ruled out that the outcome of the study would have been different with a different cutoff.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>MD Anne Sophie SÃ¸lling</name_or_title>
      <organization>Dep. of Endocrinology and Internal Medicine, Aarhus University Hospital</organization>
      <phone>78 45 54 75</phone>
      <email>annesoel@rm.dk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

